

April 5, 2021

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Atsushi Udoh, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Free Provision of Nafamostat Mesilate Products

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh; hereinafter “TOHO HOLDINGS”) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka; hereinafter “KYOSOMIRAI PHARMA”), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has decided to provide 2,000 vials of “NAFAMOSTAT MESILATE FOR INJECTION 100mg,” which is the protease inhibitor that KYOSOMIRAI PHARMA holds the marketing approval of, free of charge to Prof. Gian Paolo Rossi, MD, FACC, FAHA, Chair of Internal Medicine, Department of Medicine, University of Padua, Italy (hereinafter “Prof. Rossi”), in response to his request.

Prof. Rossi plans to conduct investigator-initiated research with drug products to be provided by KYOSOMIRAI PHARMA in order to test the hypothesis that nafamostat mesilate can lower lung function deterioration and need for intensive care admission in COVID-19 patients.

TOHO HOLDINGS is a corporate group active in medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan “Total Commitment to Good Health.” TOHO HOLDINGS will also contribute to progress in medicine.